版本:
中国

BRIEF-Alkermes Plc says initiates phase 3 gastrointestinal tolerability study of ALKS 8700

March 16 Alkermes Plc

* Alkermes Plc says initiates phase 3 gastrointestinal tolerability study of ALKS 8700 for treatment of multiple sclerosis

* Alkermes Plc says plans to submit a new drug application (NDA) for ALKS 8700 for treatment of RRMS to U.S. Food and Drug Administration (FDA) in 2018 Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐